How can exosome research improve patient management?
As the literature on exosomes continues to grow in cancer basic science, important questions remain regarding opportunities in the clinic
Healthcare budgets are still a main hurdle to global use of molecular testing for precision oncology
Inequities in access to targeted cancer treatments are due to the high costs of tests, limited number of approved medicines or clinical trials and poor communication with patients, as two new surveys report
Trials in precision oncology: current snapshot and future innovations
Increased use of molecular profiling is progressively improving decision-making processes in oncology compared with 20 years ago and helping to shape tomorrow’s clinical trials in targeted therapies
Cancer Research
Multidisciplinary Tumour Boards in harmony: mission possible?
As we all return back to practice after the busy and buzzing ESMO Congress 2021, myriad clinical questions have been addressed and debated, with many even solved. But, there is still much work to be done if we are to collectively deliver on the promise of precision medicine in oncology, and in so doing, continue to improve outcomes for our patients.
Cancer is an independent risk factor for COVID-19 mortality in hospitalised patients
Findings from international registries improve knowledge on how to manage cancer care in the pandemic era
Efficacy of COVID-19 vaccine in cancer patients is comparable to levels reported in the general population
Initial delays to antibody production are followed by similar levels of vaccine efficacy after a second vaccine dose
Some medical oncologists contemplate leaving the profession due to COVID-19
Findings from the third ESMO Resilience Task Force survey highlight the detrimental effect of long working hours and changes to clinical routine on future career plans
Rare NETs: sunitinib shows efficacy in pheochromocytoma and paraganglioma
Practice-changing results were also presented in bronchopulmonary and non-pancreatic NETs with somatostatin analogues and VEGFR inhibitors
Can immunotherapy improve the treatment of advanced neuroendocrine neoplasms?
Latest findings on the use of single-agent and combination immunotherapy are not conclusive, despite being promising
New cases of cancer are expected to reach 3.4 million in 2040 in Europe
Projections by the European Commission – Joint Research Centre from Ispra, Italy, estimate a 21.4% increase in cancer cases in 20 years’ time